Tüfekçi Özlem, Ören Hale, Demir Yenigürbüz Fatma, Gözmen Salih, Karapınar Tuba Hilkay, İrken Gülersu
Dokuz Eylül University Faculty of Medicine, Department of Pediatric Hematology, İzmir, Turkey Phone: +90 232 412 61 41 E-mail:
Turk J Haematol. 2015 Jun;32(2):175-9. doi: 10.4274/tjh.2014.0034.
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder of childhood. Major progress has been achieved in diagnosis and the understanding of the pathogenesis of JMML by identifying the genetic pathologies that occur in patients. Mutations of RAS, NF1, PTPN11, and CBL are found in approximately 80% of JMML patients. Distinct clinical features have been reported to be associated with specific gene mutations. The advent of genomic studies and recent identification of novel genetic mutations in JMML are important not only in diagnosis but also in the management and prognosis of the disease. Herein, we present 2 patients with JMML harboring different mutations, NRAS and c-CBL, respectively, with distinct clinical features and different therapeutic approaches.
青少年粒单核细胞白血病(JMML)是一种罕见的儿童克隆性骨髓增殖性疾病。通过识别患者中发生的基因病变,在JMML的诊断和发病机制理解方面取得了重大进展。约80%的JMML患者存在RAS、NF1、PTPN11和CBL突变。据报道,不同的临床特征与特定基因突变相关。基因组研究的出现以及最近在JMML中发现的新基因突变不仅对疾病的诊断很重要,而且对疾病的管理和预后也很重要。在此,我们报告2例分别携带不同突变(NRAS和c-CBL)的JMML患者,他们具有不同的临床特征和不同的治疗方法。